Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

nab-Paclitaxel (nab-P) Plus Gemcitabine (G) for Patients (Pts) With Locally Advanced Pancreatic Cancer (LAPC): Interim Efficacy and Safety Results From the Phase 2 LAPACT Trial

Date

11 Sep 2017

Session

Gastrointestinal tumours, non-colorectal

Presenters

Philip Philip

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

P.A. Philip1, J. Lacy2, F. Portales3, A. Sobrero4, R. Pazo-Cid5, J.L. Manzano-Mozo6, E.S. Kim7, S. Dowden8, A. Zakari9, C. Borg10, E. Terrebonne11, F. Rivera Herrero12, J. Shiansong Li13, T.J. Ong14, T. Nydam14, P. Hammel15

Author affiliations

  • 1 Department Of Oncology, Karmanos Cancer Institute, 48201 - Detroit/US
  • 2 Medical Oncology, Yale Cancer Center, 06510 - New Haven/US
  • 3 Oncologue Digestif, Institut régional du Cancer de Montpellier (ICM), Montpellier/FR
  • 4 Medical Oncology, Azienda Ospedaliera Universitaria San Martino, 16132 - Genova/IT
  • 5 Medical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 6 Medical Oncology, Hospital Universitari Germans Trias i Pujol, Barcelona/ES
  • 7 Medical Oncology, Levine Cancer Institute, Charlotte/US
  • 8 Medical Oncology, Tom Baker Cancer Center, T2N 4N2 - Calgary/CA
  • 9 Gastro Intestinal Cancer Program, Florida Hospital Cancer Institute, 32804 - Orlando/US
  • 10 Medical Oncology, Centre Hospitalier Belfort Montbeliard, Montbeliard/FR
  • 11 Medical Oncology, Hospital Haut Leveque, Giround/FR
  • 12 Medical Oncology, Hospital Universitario Marques de Valdecilla, 39008 - Santander/ES
  • 13 Biostatistics, Celgene Corporation - USA, 07901 - Summit/US
  • 14 Medical Affairs, Celgene Corporation - USA, 07901 - Summit/US
  • 15 Gastroenterology, Hôpital Beaujon, 92110 - Clichy/FR
More

Resources

Abstract 3096

Background

Treatment options for pts with LAPC are limited. In the phase 3 MPACT trial, nab-P + G treatment (Tx) resulted in a > 3-fold reduction in primary pancreatic tumor burden vs G in pts with metastatic PC, suggesting that the regimen may be effective in LAPC. Interim efficacy and safety results from the international, multicenter, prospective phase 2 LAPACT trial are presented.

Methods

During induction, treatment-naive pts with unresectable LAPC and ECOG PS ≤ 1 received 6 cycles of nab-P 125 mg/m2 + G 1000 mg/m2 on D 1, 8, and 15 of each 28-day cycle. After induction, pts without PD or unacceptable AEs were eligible for the investigator’s choice (IC) of continued Tx with nab-P + G, chemoradiation (CRT), or surgery. Surgery could occur prior to completing 6 cycles if the investigator deemed a sufficient tumor response. The primary endpoint was TTF. A secondary endpoint was disease control rate (DCR = CR, PR, and SD [≥ 16 weeks]) in pts who completed induction and had ≥ 1 postbaseline assessment. Data for pts who received their first dose of Tx by Oct 1, 2016 are reported.

Results

A total of 101 pts with LAPC received nab-P + G induction. Median age was 65 years (range, 42-85), and median time from primary diagnosis to first dose was 27 days. Pts received a median of 5 Tx cycles (range, 1-6). A total of 60 patients (59%) completed induction. Among 93 evaluable patients, the DCR was 82% (76/93; PR, n = 33; SD ≥ 16 wks, n = 43); 12 pts had SD 

Conclusions

The reported DCR of 82% and PR rate of 35% for nab-P + G are promising, and there were no new safety signals compared with previous studies. These interim results suggest that nab-P + G is an appropriate LAPC Tx. NCT02301143.

Clinical trial identification

NCT02301143

Legal entity responsible for the study

Celgene Corporation

Funding

Celgene Corporation

Disclosure

P.A. Philip: Research funding: Celgene, Bayer, Incyte; consultant or advisory role: Celgene; speakers’ bureau: Bayer, Roche, Sanofi, Amgen. J. Lacy, C. Borg: Research funding: Celgene. A. Sobrero: Honoraria: Bayer, Celgene, Merck, Roche, Sanofi. Consulting or advisory role: Amgen, Bayer, Merck, Pfizer; speaker’s bureau: Amgen, BMS, Merck, Sanofi. E.S. Kim: Honoraria, speaker’s bureau, advisory board: GuardantHealth; consultant: Pharmacyclics, Medallion Healthcare; advisory board: Bayer; consultant: Momenta. S. Dowden: Honoraria, advisory role, speaker’s bureau, Amgen, Bayer, Celgene, Lilly, Roche A. Zakari: Speakers bureau, Amgen, Celgene. F. Rivera Herrero: Research funding, Celgene, Bayer, Roche, Amgen, Merck-Serono, MSD, Sanofi, Lilly; consultant or advisory role, Celgene, Bayer, Roche, Amgen, Merck-Serono, MSD, Sanofi, Lilly; speaker’s bureau, Celgene, Bayer, Roche, Sanofi, Amgen, Lilly. J. Shiansong Li, T.J. Ong, T. Nydam: Employment, stock ownership: Celgene. P. Hammel: Consultant or advisory role, honoraria, travel accommodations, expenses: Celgene. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings